First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients

First in Human Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Intravenous Doses of LIS1 in Kidney Transplanted Patients

This first in human study aims at evaluating LIS1, a stabilized solution of purified anti-T lymphocytes polyclonal glyco-humanized swine IgG with immunosuppressive activity, in regards of safety, T cell depletion, and pharmacokinetics / pharmacodynamics in 10 kidney transplant recipients.

Study Overview

• Status: Completed
• Conditions: Kidney Transplant
• Intervention / Treatment: Biological: LIS1

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Czechia
  • Praha 4, Czechia, 140 21
    • Institut Klinicke A Experimentalni Mediciny

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 63 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participants must be listed for kidney transplantation,
• AD cohort participants: First transplantation, Panel Reactive Antibody (PRA) < 20%, negative Donor Specific Antibody (DSA), no anti-HLA antibodies, Epstein-Barr Virus positive (EBV+) serology,
• TD cohort participants: First transplantation, 0-50 % PRA, negative DSA, negative flow cytometry crossmatch (FCXM) for any patients with anti-HLA antibodies on screening is mandatory, Epstein-Barr Virus positive (EBV+) serology
• Participants must weigh at least 50 kg and have a Body Mass Index (BMI) 18.0 ≤ BMI < 35.0 kg/m2,
• White Blood Cells > 3000/mm3, platelets > 75000/mm3,
• Female participants (WOCBP) must have a negative pregnancy test at screening and use a highly effective birth control until 90 days after the last administration of study drug,
• Non-vasectomized male subjects having a female partner of childbearing potential must agree to the use of a highly effective method of contraception until 90 days after the last administration of study drug,
• Participants must be capable of giving signed informed consent.

Exclusion Criteria:

• Patients with an active cancer or a history of kidney cancer,
• Patients who have previously been exposed to other anti-lymphocyte globulins,
• Patients with previous organ transplantation,
• Patients with a history of specific viral infection that would contraindicate depleting antibody therapy (Hepatitis B and C, HIV),
• Patients with a positive HIV and/or Hepatitis B and C tests
• Patients who have uncontrolled concomitant bacterial or viral infections (unresolved during screening), mycosis and/or parasitosis,
• Patients with a significant liver function impairment: enzyme (AST and/or ALT) values must not exceed 1.5 times upper limit of normal,
• Patients with positive testing for tuberculosis (using QuantiFERON-TB test), Patients with CMV D+/R- constellation at transplant,
• Patients with seronegative EBV prior to transplantation,
• Patients who have previously been exposed to antibodies of swine origin,
• Expanded Criteria Donor (ECD) defined as donor older than 60 years,
• Participants who have participated in another research study involving an investigational product in the previous 3 months,
• Patients with cardiovascular or severe respiratory comorbidities (severe chronic respiratory failure, severe pulmonary fibrosis, obesity-ventilation syndrome, severe idiopathic pulmonary arterial hypertension) not allowing general anesthesia,
• Patients with type 1 diabetes,
• Participants who are pregnant, breast feeding or planning pregnancy during the study,
• Participants who have any form of substance abuse (drug, alcohol…), any other health abnormalities (psychiatric disorders) or condition that according to the investigator's opinion might endanger patient during his/her participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ascending Dose Cohort; The AD cohort will be first recruited and will include 5 patients: 1 patient per dose, sequentially recruited, the recruitment of the next dose level patient will be assessed by Data Safety Monitoring Board : Patient 1: 0.6 mg/Kg/day; Patient 2: 1 mg/Kg/day; Patient 3: 3 mg/Kg/day; Patient 4: 6 mg/Kg/day; Patient 5: 8 mg/Kg/day Once the 5 AD patients complete LIS1 treatment, the sponsor and the DSMB will rule on the LIS1 dose to obtain an optimal CD3+ cells depletion, with a good safety profile and will determine the therapeutic dose.	Biological: LIS1; LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
Experimental: Therapeutic Dose Cohort; The TD cohort will be recruited once the therapeutic dose is defined. This cohort will be divided in 2 subgroups of respectively 2 and 3 patients sequentially recruited. DSMB will review the safety and efficacy profile of the first 2 patients (Subgroup1) and decide: To continue at the same dose and recruit the next 3 patients of Subgroup 2; To recruit the next 3 patients with a lower dose, estimated from AD as bringing efficient depletion; To recruit the next patient with a higher dose (+2 mg/kg), if the depletion is not considered satisfactory and if the safety profile is considered acceptable; To end the trial if LIS1 toxicity is too important vs its efficacy in CD3+ depletion. If the decision to increase the dose after the first two TD patients is made, an additional DSMB review will be planned after patient 8. The DSMB will decide to maintain the dose for the last 2 patients or to get back to the previous dose	Biological: LIS1; LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of the treatment with LIS1: Blood pressure	Clinical safety parameters (1): Systolic and diastolic blood pressure (mm Hg).	up to 3 months after the transplant
Safety of the treatment with LIS1: Pulse rate	Clinical safety parameters (2): Pulse rate (beats per minute [bpm]) .	up to 3 months after the transplant
Safety of the treatment with LIS1: Body temperature	Clinical safety parameters (3): Body temperature (Celsius degrees).	up to 3 months after the transplant
Safety of the treatment with LIS1: Graft rejection	Clinical safety parameters (4): Graft rejection (yes/no).	up to 3 months after the transplant
Safety of the treatment with LIS1: Infection	Clinical safety parameters (5): Viral infections (namely Cytomegalovirus [CMV], BK virus) (yes/no).	up to 3 months after the transplant
Safety of the treatment with LIS1: Re-admission	Clinical safety parameters (6): Re-admission after patient discharge (yes/no).	up to 3 months after the transplant
Safety of the treatment with LIS1: Hospitalization	Clinical safety parameters (7): Prolonged stay in hospital for >4 weeks (days).	up to 3 months after the transplant
Safety of the treatment with LIS1: CRP	Laboratory parameters (1): C-Reactive Protein (CRP, mg/L).	up to 3 months after the transplant
Safety of the treatment with LIS1: LDH	Laboratory parameters (2): Lactate Dehydrogenase (LDH, µkat/L).	up to 3 months after the transplant
Safety of the treatment with LIS1: aPTT	Laboratory parameters (3): activated Partial Thromboplastin Time (aPTT, seconds).	up to 3 months after the transplant
Safety of the treatment with LIS1: Complete Blood Count (CBC)	Laboratory parameters (4): Platelets (10^9/L), white blood cells (10^9/L), absolute neutrophil count (10^9/L), absolute lymphocyte count (10^9/L), absolute monocyte count (10^9/L), absolute eosinophil count (10^9/L), absolute basophil count (10^9/L).	up to 3 months after the transplant
Pharmacodynamics (depletion of T lymphocytes) of LIS1	Absolute T lymphocyte counts (10^9/L).	up to 3 months after the transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics of LIS1 (1): swine IgG	Serum concentration of swine IgG	up to 3 months after the transplant
Pharmacodynamics of LIS1 (2): cytokines	Cytokine concentration (IL6, TNFα) (ng/mL).	up to 3 months after the transplant
Biology of LIS1 (1): electrolytes plasma concentration	Plasma biochemistry: electrolytes (Na+, K+, Cl-, Ca++, Mg++, bicarbonates plasma concentrations mmol/L)	up to 3 months after the transplant
Biology of LIS1 (2): urea and creatinine	Plasma biochemistry: urea and creatinine plasma concentration (mmol/L)	up to 3 months after the transplant
Biology of LIS1 (3): total plasma proteins	Plasma biochemistry: Total protein plasma concentration (g/L)	up to 3 months after the transplant
Biology of LIS1 (4): plasmatic proteins	Plasma biochemistry: electrophoresis of plasmatic proteins (percentages of albumin, alpha-1-globulin, alpha-2-globulin, beta-globulin, gamma-globulin)	up to 3 months after the transplant
Immunogenicity of LIS1	Detection of antidrug antibodies in serum	up to 3 months after the transplant

Collaborators and Investigators

• Sponsor: Xenothera SAS
• Investigators: Principal Investigator: Dr Ondrej Viklicky, Institut klinické a experimentální medicíny, Praha 4, Czech Republic

Study record dates

Study Major Dates

• Study Start (Actual): November 26, 2019
• Primary Completion (Actual): March 28, 2022
• Study Completion (Actual): March 28, 2022

Study Registration Dates

• First Submitted: May 28, 2020
• First Submitted That Met QC Criteria: June 10, 2020
• First Posted (Actual): June 16, 2020

Study Record Updates

• Last Update Posted (Actual): August 17, 2022
• Last Update Submitted That Met QC Criteria: August 16, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: immunosuppression; polyclonal IgG; allograft transplantation; induction treatment; acute graft rejection
• Other Study ID Numbers: XT-1901

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No